Medical Devices
100 VCs and 14 funds investing in Medical Devices
VCs investing in Medical Devices
Alex Morgan
Partner
Khosla Ventures
Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.
Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.
Arielle Rothman
Investor
BoxGroup
Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.
Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.
Aristos Doxiadis
Partner Emeritus
Big Pi Ventures
Check: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.
Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.
Charlie Plauche
Managing Director
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Charlie Plauche is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Kevin Haley
Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Kevin Haley is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Eric Engineer
General Partner
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Eric Engineer is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Nicole Bentz
Vice President
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Nicole Bentz is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Joe Curry
Principal
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Joe Curry is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Oscar Moralez
Founder and Managing Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Anthony Marfisi
Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Anthony Marfisi is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Wayne Wallace
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Will Omberg
Senior Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Will Omberg is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Kathryn Deebel
Director of Platform & Network
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Kathryn Deebel is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Shelley Graves
Controller
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Shelley Graves is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Ariel MacTavish
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
J. Carter McNabb
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
J. Carter McNabb contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Audrey Beckman
Partner and Chief Innovation Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Dick Aderman
Studio Director
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Britney Hamberg
Principal, Investor Relations & Operations
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Britney Hamberg contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Todd R. Lugar
Controller and HR Lead
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Tony Petrucciani
Partner and Chief Financial Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Bill Trainor
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Britney Byrd
Analyst, Finance
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Britney Byrd contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Ally Thill
Project Leader
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Dan Clark
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
David Helmer
Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Eric Beier
Partner and Chief Medical Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Tejas Vijh
Associate
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Liz Todia Zambory
Principal
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Will Brune
Senior Associate
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Alain Horvais
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Amanda Gett
Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Robert Heimann
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Robert Heimann contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Rurik “Rik” Vandevenne
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Rurik “Rik” Vandevenne contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Patrick Dunnigan
Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Patrick Dunnigan contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Adrienne Vannarsdall
CFO
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Adrienne Vannarsdall contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Parag Rathi
Principal
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Parag Rathi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Vitaly Goldfeder
Principal
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Vitaly Goldfeder contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Sonny Guilhem
Senior Financial Controller
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Dana Tanenbaum
Controller
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Dana Tanenbaum contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Paul Axelrod
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Paul Axelrod contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Scott Steever
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Scott Steever contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Ryan Moeller
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Ryan Moeller contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Marcus Fields
Senior Associate
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Marcus Fields contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Saloni Rai
Analyst, Investor Relations
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Saloni Rai contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Kushal Modi
Analyst, Investments
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Kushal Modi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Federica Porcu
Financial Controller and ESG Manager
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Federica Porcu.
Federica Porcu serves Panakès Partners as Financial Controller and ESG Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.
Kaity Lynch
Manager of Administration
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Kaity Lynch contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Jim Adox
Managing Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Scott Button
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Paul Weiss
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
David Arnstein
Partner and Chief Financial Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
John Neis
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Joe Amaral, MD
Chief Medical and Scientific Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Jenni Le
Principal
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Margaret Kaczor Andrew
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Cheryl R. Blanchard, PhD
Executive in Residence
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Shelly Lanning
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Becky Hoerman
Controller
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Linda Olson
Office Manager
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Benjamin Belot
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Rémi Droller
Managing Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Daniel Fleming
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Daniel Fleming contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Alex Shandiz
General Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Thierry Laugel
Managing Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Peter Neubeck
Partner Germany, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Daniel Parera
Partner Germany, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Philippe Peltier
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Jean-François Rivassou
Partner, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Hadrien Bouchez
Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Laura Achach
Associate, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Samantha Zennou
Associate, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Florence de Coorebyter
Associate, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Anna Tchorzewska
Associate, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Maylis Deschamps
Associate, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Louise-Marie Rakotoarison
Analyst, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Muriel Domine
Secretary General, Head of Compliance & Legal
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Cyril Bedran
Financial Director
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Aaron Perman
General Partner
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Aaron Perman is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Ornella Gomis
Financial Controller
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Steffi Minga
Office Manager
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Fatima Boubnad
Management Assistant
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Fabrizio Landi
Founder and Managing Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Fabrizio Landi.
Fabrizio Landi works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Alessio Beverina
Founder and Managing Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Beverina.
Alessio Beverina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Diana Saraceni
Founder and Managing Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Diana Saraceni.
Diana Saraceni works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Barbara Castellano
Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Barbara Castellano.
Barbara Castellano works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Rob Woodman
Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Rob Woodman.
Rob Woodman works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Marco Sardina
Scientific Partner
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Marco Sardina.
Marco Sardina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Alessio Piuma
Principal
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Piuma.
Alessio Piuma works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Andrea Ballerini
Investment Manager
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Andrea Ballerini.
Andrea Ballerini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Giacomo Piccinini
Investment Manager
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Giacomo Piccinini.
Giacomo Piccinini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Annalisa Coraducci
Senior Analyst
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Annalisa Coraducci.
Annalisa Coraducci works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Lorenzo Giordano
Chief Financial Officer
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Lorenzo Giordano.
Lorenzo Giordano serves Panakès Partners as Chief Financial Officer. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.
Paola Crovato
Office and Deal Flow Manager
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Paola Crovato.
Paola Crovato serves Panakès Partners as Office and Deal Flow Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.
Brian R. Smith
Managing Director
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Brian R. Smith is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Michela Barcella
Network and Portfolio Talent Advisor
Panakès Partners
Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Michela Barcella.
Michela Barcella serves Panakès Partners as Network and Portfolio Talent Advisor. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.
Karel Kubias, MBA
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Ivan Vohlmuth
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Barbora Šumová, Ph.D.
Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Barbora Šumová, Ph.D. invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Tomáš Maršálek, MBA
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Tomáš Maršálek, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Funds focused on Medical Devices
Gilde Healthcare
Utrecht, Netherlands
NLC Health Ventures
Amsterdam, Netherlands
Wellington Partners
Munich, Germany
Kurma Partners
Paris, France / Munich, Germany
Hadean Ventures
Oslo, Norway and Stockholm, Sweden
RC Capital
Cincinnati, Ohio / Raleigh, North Carolina
Newton Biocapital
Brussels, Belgium and Tokyo, Japan
Panakès Partners
Milan, Italy
Boomerang Ventures
Indianapolis, Indiana
Clarevia
Madison, Wisconsin
S3 Ventures
Austin, Texas
i&i Bio
Prague, Czechia
Vesalius Biocapital
Luxembourg
Mutual Capital Partners
Westlake, Ohio